Strados Labs Adds Health Leaders to Management Team

Strados Labs, creator of the world’s first remote respiratory monitoring platform, has addrf three new executives to its management team. Strados Labs’ remote respiratory monitoring platform gives clinicians access to real-time information about changes in their patients’ lung health, allowing proactive interventions to improve pulmonary health and reduce readmissions.

“I am very excited that we have this depth of experience at Strados Labs,” said CEO and Founder Nick Delmonico, CPA, MBA. “Richard and Jason have unmatched experience in the emerging field of remote clinical monitoring, and will help Strados Labs accelerate the final development and commercialization of our platform. Dr. Glass has been a part of five successful drug launches and IPO teams, and his experience with pulmonary critical care at the University of Pennsylvania will be invaluable to our clinical validity.”

Joining the Strados Labs team are:

Richard Powers, MSE, MBA, as chief operating officer. Powers is the former chief information officer (CIO) of CardioMEMS, a remote cardiac monitoring solution that experienced a successful $455 million exit. Under his leadership at CardioMEMS, Powers and his team designed and developed a secure, cloud-based, remote healthcare monitoring disease management IoT platform powering the world’s first U.S. Food and Drug Administration-approved implantable wireless blood pressure sensor for patients with heart failure. He also served as CIO of Endotronix which provides hemodynamic monitoring solutions to help detect worsening heart failure. Powers received a BEE, electrical engineering, and MSECE, electrical and computer engineering, from the Georgia Institute of Technology. He completed his MBA at the Georgia Tech’s Scheller College of Business.

Mitchell Glass, M.D., as chief medical officer (CMO). Dr. Glass is a 30-year veteran of the pharmaceutical industry. His experience is broad, ranging from senior positions in top 10 pharmaceutical companies to investment in and management of start-ups and biotechs. His experience includes serving as vice president and director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, as well as chief medical officer and vice president of Clinical Development and Regulatory Affairs of AtheroGenics Inc., where he led product development from IND to initiation of Phase 3 for AGI 1067 and was a member of the IPO team. He is the chairman of Accolade Pharmaceuticals and has been a director of OrphageniX Inc. (gene editing) and AVATAR Biotechnologies (biosimilars), as well as executive vice president of R&D and CMO of Invion Ltd. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.

Jason Kroh, MSE, as chief technology officer. Kroh has a wide range of experience in medical electronics development, bringing more than two decades of experience to Strados Labs. Prior to joining Strados, he served as vice president of New Product Development for Vero Biotech and vice president of Hardware and Biomedical Engineering for Sarvint Technologies. He was vice president of R&D, Electrical Engineering, for CardioMEMS, where he established and managed a multidisciplinary team of engineers and technicians to design and develop the company’s proprietary electronics platform. Kroh was the lead electrical engineer at Cybersonics Inc., where he designed and developed the electronics for the control and actuating mechanisms for therapeutic ultrasonic medical devices. Kroh has a bachelor of science degree in biomedical engineering from Boston University and a master of science degree in electrical engineering from Gannon University. He holds 26 issued U.S. patents and has co-authored multiple papers on sensing and actuation.

Strados Labs has developed the first system that objectively measures cardiopulmonary health, allowing providers to remotely monitor at-risk patients using a novel biosensor and clinically validated analytics platform. With the Strados Labs system, clinical teams can access and monitor real-time changes in lung health so they can intervene to improve patient outcomes while reducing readmissions.